| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 12:58 | Judge blocks HHS' 340B rebate pilot at 11th hour | ||
| Mo | J&J abandons trial of atopic dermatitis drug | ||
| Mo | No Christmas present for Sanofi, as FDA turns down MS drug | ||
| Mo | Biosimilars unlock use of bevacizumab in bowel cancer by NHS | ||
| Mi | CMS aims for broader GLP-1 access via federal programmes | ||
| Mi | Sanofi swoops on Dynavax with $2.5bn takeover deal | ||
| 23.12. | Trump raises spectre of drug pricing mandates for Medicare | ||
| 23.12. | Novo Nordisk gets FDA okay for Wegovy pill | ||
| 22.12. | Andexxa reaches the end of the line in the US | ||
| 22.12. | Ipsen licenses Simcere ADC in $1bn-plus deal | ||
| 22.12. | AZ's ATR inhibitor ceralasertib flunks lung cancer test | ||
| 22.12. | Nine more companies sign pricing deals with Trump | ||
| 22.12. | BioMarin ends year with $4.8bn play for Amicus | ||
| 19.12. | US BIOSECURE Act passed by Congress | ||
| 18.12. | CEPI steps in to fund Moderna's pandemic flu jab | ||
| 18.12. | Ambros' $125m for pain disorder drug, and other financings | ||
| 18.12. | J&J's subcutaneous Rybrevant cleared by FDA | ||
| 18.12. | As year-end nears, pharma groups plump up their pipelines | ||
| 18.12. | Lilly points to long-lasting weight loss with orforglipron | ||
| 18.12. | Datroway filed for TNBC in EU after data delay | ||
| 18.12. | Takeda plans filings for Sotyktu rival on new psoriasis data | ||
| 18.12. | MSD claims two national priority vouchers; report | ||
| 18.12. | As year-end nears, pharma groups boost their pipelines | ||
| 17.12. | Padcev/Keytruda scores again in early bladder cancer | ||
| 17.12. | DBV gets peanut allergy therapy programme back on track |